

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
February 24, 2015**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933**

Bellerophon Therapeutics, Inc.

File No. 333-201474 - CF#31194

Bellerophon Therapeutics, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on January 13, 2015, as amended.

Based on representations by Bellerophon Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.8	through July 1, 2017
Exhibit 10.10	through May 14, 2017
Exhibit 10.11	through February 8, 2016
Exhibit 10.12	through May 14, 2017
Exhibit 10.13	through May 14, 2016
Exhibit 10.14	through May 14, 2017
Exhibit 10.15	through February 9, 2016

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary